血清bFGF、E2及尿bFGF对婴幼儿血管瘤和脉管畸形的诊断意义

目的:探讨血清碱性成纤维细胞生长因子(bFGF)、雌二醇(E2)及尿bFGF在血管瘤和脉管畸形患者中的表达差异,为血管瘤和脉管畸形的鉴别诊断提供客观依据.方法:研究对象为78例增殖期血管瘤患者、18例消退期血管瘤患者及25例脉管畸形患者的血清和尿上清液,阴性对照为48例单纯唇腭裂患者,所有患者年龄均≤30个月.应用酶联免疫吸附分析法(ELISA)检测各组血清和尿bFGF浓度,并对尿bFGF浓度进行尿肌酐平衡;应用放射免疫方法(RlA)检测各组血清E2浓度.采用SPSS11.5软件包对数据进行统计学处理.结果:血管瘤患者血清bFGF浓度>脉管畸形患者血清bFGF浓度>对照组血清bFGF浓度,3组之间浓度有显著差异(P=0.027);血管瘤患者尿bFGF浓度>脉管畸形患者尿bFGF浓度>对照组尿bFGF浓度,3组之间浓度有显著差异(P=0.000);增殖期血管瘤患者尿bFGF浓度显著高于消退期血管瘤患者(P=0.04);血管瘤、脉管畸形患者和对照组3组之间血清E2浓度有显著差异(P=0.000);脉管畸形患者和对照组的血清E2浓度无显著差异(P>0.05).结论:血清、尿bFGF浓度可作为血管瘤鉴别诊断的指标,血清E2浓度可用于诊断血管瘤和脉管畸形并判断血管瘤是否处于增殖期.

Basic fibroblast growth factor and estradiol for the diagnosis of infantile hemangiomas and vascular malformations

PURPOSE： To investigate the significance of serum basic fibroblast growth factor （bFGF）, estradiol （E2） and urinary bFGF in differentiating infantile hemangiomas from vascular malformations. METHODS： Between October 2007 and January 2009, 96 patients with hemangiomas and 25 patients with vascular malformations without any treatment were included in this prospective study. 48 patients with single cleft lip or palate were selected as negative control. The age of all selected cases ranged from 1 to 30 months. The serum and urine of all patients were preserved for later test. The serum and urinary levels of bFGF were determined with enzyme linked immunosorbent assay （ELISA）. The serum levels of E2 were examined via RIA. The data were analyzed with SPSS 15.0 software package. RESULTS： The concentration of serum bFGF was significantly different among hemangioma, vascular malformation and negative control group （P=0.027）, The concentration of urinary bFGF was significantly different among hemangioma, vascular malformation and negative control group （P=0.000）; The concentration of serum E2 was significantly different among hemangioma, vascular malformation and negative control group（P=O.OOO）,and it was significantly higher in patients with hemangioma than that in other two groups. CONCLUSION： Serum and urinal＇ bFGF may be potential markers for diagnosing proliferating hemangiomas of infancy. Serum E2 can be used to diagnose hemangiomas and determining the proliferating stage of hemangioma.